Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.72 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464129 | 0.84 | MEN1 (1.00) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL4362841 | 0.83 | KDM4E (1.00) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL17406875 | 0.82 | MEN1 (0.51) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL3157350 | 0.81 | MEN1 (1.00) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL17609473 | 0.77 | POLB (0.71) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL19327437 | 0.76 | POLB (0.69) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL8089684 | 0.75 | MEN1 (0.56) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL8084587 | 0.75 | KMT2A (0.67) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL11345433 | 0.75 | EGFR (0.68) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL3157071 | 0.74 | KDM4E (0.55) | MEN1KMT2ANR2F2KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981968-B2 | Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders | NORTHWESTERN UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981968-B2 | Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders | NORTHWESTERN UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160002252-A1 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002252-A1 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2016-01-07 | — | — | US | disclosed |
| US-8697713-B2 | Pyrrolopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | disclosed |
| US-8697713-B2 | Pyrrolopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | disclosed |
| US-20100105708-A1 | PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105708-A1 | PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-1889847-A1 | Pyrrolopyrimidines for pharmaceutical compositions | DeveloGen Aktiengesellschaft (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008006547-A2 | PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2008-01-17 | — | — | WO | disclosed |
| US-6096749-A | ANTITUMOR, EPIDERMAL GROWTH FACTOR | NOVARTIS CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0682027-B1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA GEIGY AG (CH) | 1997-10-15 | — | — | EP | disclosed |
| EP-0682027-A1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA-GEIGY AG (CH) | 1995-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002252-A1 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | DPYD, TYMP, TYMS | MEN1 3694/4885KMT2A 2515/4885NR2F2 1980/4885 |
| US-20100105708-A1 | PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DMPK, PNKP, CMPK1 | MEN1 1204/4885KMT2A 1274/4885NR2F2 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.